Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

Next Previous
Trial Profile

A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivuxolimab (Primary) ; Utomilumab (Primary)
  • Indications Bladder cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer; Uterine cancer; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer

    • Most Recent Events

    • 06 Oct 2021 Interim results (n=52) assessing the dose-escalation portion of the first-in-human phase I study of ivuxolimab in patients with locally advanced or metastatic cancers and analysis of biomarker studies is presented in parallel to support the immunomodulatory effects of ivuxolimab, published in the Clinical Cancer Research.
    • 22 Dec 2020 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2020 Planned End Date changed from 30 Jun 2020 to 22 Dec 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top